Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05063149

Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates. (PROTEA)

Protecting Late-moderate Preterm Infants From Respiratory Tract Infections and Wheeze in Their First Years of Life by Using Bacterial Lysates.

Sponsor: Franciscus Gasthuis

Conditions LRTI Premature Wheezing

Interventions Broncho-Vaxom Placebo

Updated 5 times since 2021 Last updated: Aug 20, 2024 Started: Jan 18, 2022 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on LRTI and Premature, this trial is actively recruiting participants. The trial is conducted by Franciscus Gasthuis and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Mar 2022 — Mar 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Franciscus Gasthuis
Leiden University Medical Center
Maastricht University Medical Center

Data source: Franciscus Gasthuis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rotterdam, Netherlands